Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients
| Autor: | Henk-Jan Guchelaar, Johan W. R. Nortier, Ninja Antonini, Dina M. Kweekel, Cornelis J. A. Punt, Hans Gelderblom, Tahar van der Straaten |
|---|---|
| Přispěvatelé: | Other departments |
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Genotype Organoplatinum Compounds Colorectal cancer Deoxycytidine Gastroenterology Capecitabine GSTP1 Immune Regulation [NCMLS 2] Translational research [ONCOL 3] Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Genetic Predisposition to Disease Codon neoplasms Aged Aged 80 and over Polymorphism Genetic Hereditary cancer and cancer-related syndromes [ONCOL 1] business.industry Cancer Middle Aged medicine.disease Oxaliplatin Treatment Outcome Glutathione S-Transferase pi Oncology Immunology Toxicity Female Neurotoxicity Syndromes Fluorouracil Colorectal Neoplasms Epidemiologic Methods business medicine.drug |
| Zdroj: | European journal of cancer (Oxford, England, 45(4), 572-578. Elsevier Limited European Journal of Cancer, 45, 4, pp. 572-8 European Journal of Cancer, 45, 572-8 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/j.ejca.2008.10.015 |
| Popis: | Item does not contain fulltext PURPOSE: Oxaliplatin is detoxified by conjugation to glutathione via the enzyme Glutathione-S-transferase pi (GSTP1). The aim of this study is to investigate the association of GSTP1 Ile105Val genetic polymorphism with oxaliplatin efficacy and toxicity in advanced colorectal cancer (ACC) patients. EXPERIMENTAL DESIGN: A total of 91 ACC patients received capecitabine and oxaliplatin (CAPOX) as a part of a multicentre phase-III study of the Dutch Colorectal Cancer Group. Tumour response was evaluated according to RECIST, toxicity was graded using CTC, and GSTP1 Ile105Val was determined by pyrosequencing. RESULTS: Overall survival after CAPOX was similar for patients with the Ile/Ile (11.5 mo), Ile/Val (11.6 mo) and Val/Val (12.6 mo) genotypes (p=0.602). Likewise, there were no statistically significant differences in progression-free survival (p=0.252). Overall grades 3-4 toxicity was not related to genotype (p=0.313). There were no differences in any grade or grades 3-4 neurotoxicity amongst the patients who received > or =500 mg/m(2) of oxaliplatin (p-values of 0.376 and 0.772, respectively). CONCLUSIONS: The results of this study indicate that the GSTP1 genotype is not predictive for progression-free survival or overall survival in ACC patients treated with CAPOX. Moreover, overall neurotoxicity and neurotoxicity in patients receiving 500 mg/m(2) of oxaliplatin was not associated with GSTP1 genotype. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect